-[15]
12, 303 -[30] 4, 005 -[19] 18,328 - [6] 18,328 - [6] 18,328 - [6] 319 - [6] 611 - [6] 17, 214 -[6,25] 2,561 - [30] 0 - [*] 3,063 - [30] 1, 088 -[18] 6,056 - [3] 465 - [3] 4, 290 -[3] 4, 290 -[3] 4, 290 -[3] 95 - [23] 895 - [3] 1, 868 -[3] 1, 391 -[3] 0 - [*] 1,391 - [3] 575 - [9] 12, 055 -[4] 7,952 - [4] 11, 045 -[14,21] 5,302 - [4] 5, 302 -[4] 378 - [24] 3, 785 -[4] 115 - [17] 3, 741 -[4] 0 - [*] 3, 741 -[4] * Assumed to be associated with no medical cost 
Conclusion
This study provides a coherent set of costs identi ed through literature review for diabetes complications in four European countries. An e ort was made to use consistent assumptions to facilitate the comparison. Nevertheless, most of the costs identi ed only accounted for the expenses of acute events such as myocardial infarction but not additional medical costs (i.e. additional follow-up costs, complication costs). Notwithstanding, this study is a useful source of cost data in the absence of more robust research. Future research would bene t from large-scale multi-country patient-level data collection which could reveal the true economic burden of diabetes.
Limitations
This study presents several limitations due to the di erences in health care system structures and in cost transparency. The cost estimation methodology varied among countries and was not always directly comparable. Diagnostic related group (DRG) tari s were used to estimate several costs which may not accurately represent the burden of a speci c complication nor take into account the full burden of follow-up after an acute event. The DRG costs do not re ect the fact that events in diabetic patients tend to be more costly than for the non-diabetic counterparts. There were also a limited number of published articles for several complications in all four countries. The published studies had disparate methodologies and were often conducted in a speci c region or hospital which limits the applicability of the elicited cost to a national level.
Results Table 1 to 3 present a summary of the yearly costs associated with diabetes complications in four European countries for use in economic modeling.
The costs of cardiovascular complications were similar in the four countries.
The cost for dialysis appeared to be higher in France. This is because a comprehensive costing publication was used in France whereas in the three other countries the only information available was the DRG codes for the dialysis treatment.
The cost of visual impairment and neuropathy complication varied widely due to the di erent valuation methods and the nature of the complications.
Methods
A search for published cost of diabetes complications data was performed on government websites, public databases and peer-reviewed journals. Costs were collected and reviewed by local cost experts.
The national health care payer perspective was adopted. A consistent approach in the in the valuation of the di erent complications was applied whenever possible.
For the costs of drugs, the cheapest and most frequently used product in the therapeutic class was selected.
Introduction
Diabetes mellitus (T2DM) represents a major public health burden. To understand its economic consequences and assess the cost-e ectiveness of di erent interventions, health economic modeling is commonly used. Diabetes complications are the main driver of the cost of the disease. Due to the large number and variability of diabetes complications, evaluating their medical cost is challenging.
Diabetes complication costs compiled in a systematic manner would help to determine and compare reliable estimates of the economic burden of the disease across countries. 
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